News

Innovative Findings on WRAPSODY's Effectiveness in Vascular Access

Innovative Findings on WRAPSODY's Effectiveness in Vascular Access

Merit Medical Unveils Significant Results from WAVE Trial

Merit Medical Systems, Inc. (NASDAQ: MMSI) has recently shared promising findings regarding the 12-month results from the WAVE trial's single-arm cohort, showcasing innovative advancements in healthcare technology. This study was presented at the prestigious Charing Cross Symposium, where experts from around the world gathered to discuss breakthroughs in vascular access solutions.

The WAVE Trial Overview

The WAVE trial's single-arm cohort involved 112 patients treated with the unique WRAPSODY CIE device, aimed at addressing challenges faced by patients with failing arteriovenous grafts (AVGs). The results showcase exceptional promise, highlighting a 6-month total lumen patency percentage (TLPP) of 81.4%. This figure exceeds the established performance goal of 60% by an impressive 21.4 percentage points, marking a significant achievement in the trial.

Key Efficacy Findings

At the 6-month mark, the proportion of patients free from adverse events also exceeded expectations, with a safety rate of 95.4%, surpassing the goal of 89%. By the 12-month evaluation, the TLPP associated with WRAPSODY maintained a noteworthy level at 60.2%. Furthermore, the access circuit primary patency (ACPP) rates were recorded at 69.2% and 36.2% for 6 and 12 months, respectively, cementing the device's efficacy within the vascular access sphere.

Expert Insights on WRAPSODY

The significance of these results is echoed by Robert G. Jones, MBChB, FRCR, a consultant interventional radiologist and co-principal investigator of the WAVE trial. He emphasized the limited options available to patients with failing AVGs and the critical role WRAPSODY may play in enhancing patient care. Sharing findings at the symposium not only raises awareness but provides valuable insights for colleagues treating similar patient demographics.

Looking Forward

Fred P. Lampropoulos, the Chairman and CEO of Merit Medical, expressed enthusiasm in disseminating these results to physician partners. His commitment to partnering with healthcare professionals aims to foster continuous improvement in patient outcomes, aligning with Merit’s mission to innovate within the healthcare technology landscape.

Study Comparisons and Broader Implications

It's worth noting that findings from the randomized arm of the WAVE trial had previously reported TLPP and ACPP rates of 70.1% and 58.1%, respectively. These comparisons underline the robust performance of the WRAPSODY device over traditional methods. The earlier reported 6-month efficacy results of 89.8% TLPP and 72.6% ACPP demonstrate consistency in the device's effectiveness across varied patient groups.

Availability and Next Steps

Currently, the WRAPSODY CIE is accessible in Brazil and the European Union and is also approved for commercial distribution within the United States. As Merit Medical expands its footprint, healthcare providers and patients alike can look forward to the continued development and availability of cutting-edge medical solutions that enhance vascular access procedures.

About Merit Medical Systems, Inc.

Founded in 1987, Merit Medical has grown to become a vital player in the development, manufacture, and distribution of medical devices across diverse therapeutic areas. The company is dedicated to producing proprietary disposable medical devices that support a variety of procedures, including cardiology, oncology, and critical care. With a dedicated workforce of over 7,300 employees globally, Merit Medical strives to provide hospitals with the innovative tools needed to improve patient care.

Frequently Asked Questions

What is the WRAPSODY CIE device?

It is a medical device developed by Merit Medical for use in arteriovenous grafts to enhance vascular access and functionality.

What were the main findings of the WAVE trial?

The trial demonstrated a 6-month TLPP of 81.4% and a safety rate of 95.4%, showcasing the device's effectiveness.

Where is the WRAPSODY device available?

WRAPSODY is currently available in Brazil, the European Union, and is approved for distribution in the United States.

What is Merit Medical's mission?

Merit Medical aims to innovate and provide healthcare professionals with medical technologies that improve patient outcomes across various fields.

Who is the CEO of Merit Medical?

Fred P. Lampropoulos serves as the Chairman and Chief Executive Officer of Merit Medical Systems, Inc.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 0

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Frontline Healthcare Partners Secures Integracare Inc. Deal

Updated Category News Views 161

Frontline Healthcare Partners Expands Through Strategic Acquisition Frontline Healthcare Partners has recently made headlines with its strategic acquisition of Integracare Inc.. This move indicates a significant step forward in enhancing its portfolio within the private home healthcare space. With Integracare’s reputation for quality care in Toronto and Mississauga,...

Continue Reading
WiMi Innovates with Advanced FPGA-Based Quantum Computing Tech

Updated Category News Views 147

WiMi Hologram Cloud Inc. Develops Cutting-Edge Quantum Computing Technology WiMi Hologram Cloud Inc. (NASDAQ: WiMi), a global leader in Hologram Augmented Reality (AR) technology, has achieved a remarkable milestone by developing a digital quantum computer verification technology based on Field-Programmable Gate Array (FPGA). This advancement signifies a transformative...

Continue Reading
KSP Achieves Excellence in Specialty Pharmacy Recognition Again

Updated Category News Views 244

KSP Recognized as a Specialty Pharmacy Leader KSP, part of McLaren's Specialty Pharmacy, has once again been honored for its outstanding achievements in performance measurement. The Utilization Review Accreditation Commission (URAC) has recognized KSP as a 2024 Specialty Pharmacy Pioneer in its Leaders in Performance Measurement (LPM) program. This accolade underlines...

Continue Reading
Why IREN Limited Shares Are Under Pressure Today in Market

Updated Category News Views 237

Understanding the Recent Drop in IREN Limited Stock IREN Limited (NASDAQ: IREN) has experienced a noticeable decline in share price today as investors react to the company's recent announcements. This comes as a surprise to some, as IREN has shown potential for growth in the past year. Recent Announcements from IREN Limited In a recent update, IREN Limited unveiled plans...

Continue Reading
Deutsche Bank Adjusts S&P 500 Forecast to 5,750 Points

Updated Category News Views 57

Deutsche Bank Updates S&P 500 Year-End Forecast Deutsche Bank has adjusted its year-end target for the S&P 500 index, now forecasting it to reach 5,750 points, up from the previous estimate of 5,500. This significant change stems from strong corporate earnings, an increase in stock buybacks, and a solid demand for equities among investors. Positive Earnings Growth Ahead...

Continue Reading